相似文献
1
In vitro synergy studies with Clostridium difficile.
Antimicrob Agents Chemother. 1991 Mar;35(3):582-3. doi: 10.1128/AAC.35.3.582.
2
Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin.
Antimicrob Agents Chemother. 2002 Jun;46(6):1647-50. doi: 10.1128/AAC.46.6.1647-1650.2002.
3
Analysis of anti-Clostridium difficile activity of thuricin CD, vancomycin, metronidazole, ramoplanin, and actagardine, both singly and in paired combinations.
Antimicrob Agents Chemother. 2013 Jun;57(6):2882-6. doi: 10.1128/AAC.00261-13. Epub 2013 Apr 9.
4
Antimicrobial susceptibility pattern of Clostridium difficile and its relation to PCR ribotypes in a Swedish university hospital.
Antimicrob Agents Chemother. 2006 May;50(5):1890-2. doi: 10.1128/AAC.50.5.1890-1892.2006.
5
Antimicrobial susceptibilities and serogroups of clinical strains of Clostridium difficile isolated in France in 1991 and 1997.
Antimicrob Agents Chemother. 1999 Nov;43(11):2607-11. doi: 10.1128/AAC.43.11.2607.
6
In vitro activities of CB-183,315, vancomycin, and metronidazole against 556 strains of Clostridium difficile, 445 other intestinal anaerobes, and 56 Enterobacteriaceae species.
Antimicrob Agents Chemother. 2012 Mar;56(3):1613-5. doi: 10.1128/AAC.05655-11. Epub 2011 Dec 19.
7
Repurposing a platelet aggregation inhibitor ticagrelor as an antimicrobial against Clostridioides difficile.
Sci Rep. 2020 Apr 16;10(1):6497. doi: 10.1038/s41598-020-63199-x.
8
Antimicrobial susceptibility of Brazilian Clostridium difficile strains determined by agar dilution and disk diffusion.
Braz J Infect Dis. 2016 Sep-Oct;20(5):476-81. doi: 10.1016/j.bjid.2016.07.004. Epub 2016 Aug 16.
9
Diversity of Circulating Ribotypes in Mexico and Susceptibility to Fidaxomicin, Vancomycin, and Metronidazole.
Microb Drug Resist. 2021 Dec;27(12):1672-1676. doi: 10.1089/mdr.2020.0583. Epub 2021 May 25.
10
In vitro activities of ramoplanin, teicoplanin, vancomycin, linezolid, bacitracin, and four other antimicrobials against intestinal anaerobic bacteria.
Antimicrob Agents Chemother. 2003 Jul;47(7):2334-8. doi: 10.1128/AAC.47.7.2334-2338.2003.
引用本文的文献
1
Bacteriocin-Antimicrobial Synergy: A Medical and Food Perspective.
Front Microbiol. 2017 Jun 29;8:1205. doi: 10.3389/fmicb.2017.01205. eCollection 2017.
2
The efficacy of thuricin CD, tigecycline, vancomycin, teicoplanin, rifampicin and nitazoxanide, independently and in paired combinations against Clostridium difficile biofilms and planktonic cells.
Gut Pathog. 2016 Jun 2;8:20. doi: 10.1186/s13099-016-0102-8. eCollection 2016.
3
Clostridium difficile infection among hospitalized HIV-infected individuals: epidemiology and risk factors: results from a case-control study (2002-2013).
BMC Infect Dis. 2015 Apr 22;15:194. doi: 10.1186/s12879-015-0932-x.
4
Analysis of anti-Clostridium difficile activity of thuricin CD, vancomycin, metronidazole, ramoplanin, and actagardine, both singly and in paired combinations.
Antimicrob Agents Chemother. 2013 Jun;57(6):2882-6. doi: 10.1128/AAC.00261-13. Epub 2013 Apr 9.
5
Frequent emergence of resistance in Clostridium difficile during treatment of C. difficile-associated diarrhea with fusidic acid.
Antimicrob Agents Chemother. 2006 Sep;50(9):3028-32. doi: 10.1128/AAC.00019-06.
6
Clostridium difficile infection: a common clinical problem for the general internist.
J Gen Intern Med. 1994 Sep;9(9):528-33. doi: 10.1007/BF02599229.
本文引用的文献
1
Antagonists of nucleic acid derivatives. VIII. Synergism in combinations of biochemically related antimetabolites.
J Biol Chem. 1954 Jun;208(2):477-88.
2
Treatment of Clostridium difficile colitis and diarrhea with vancomycin.
Am J Med. 1981 Nov;71(5):815-22. doi: 10.1016/0002-9343(81)90369-7.
3
The fractional inhibitory concentration (FIC) index as a measure of synergy.
J Antimicrob Chemother. 1983 May;11(5):427-33. doi: 10.1093/jac/11.5.427.
4
Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis.
Lancet. 1983 Nov 5;2(8358):1043-6. doi: 10.1016/s0140-6736(83)91036-x.
5
Antibiotic-associated colitis due to Clostridium difficile: double-blind comparison of vancomycin with bacitracin.
Gastroenterology. 1985 Nov;89(5):1038-45. doi: 10.1016/0016-5085(85)90206-9.
6
Therapy of relapsing Clostridium difficile-associated diarrhea and colitis with the combination of vancomycin and rifampin.
J Clin Gastroenterol. 1987 Apr;9(2):155-9. doi: 10.1097/00004836-198704000-00009.
7
Oral bacitracin vs vancomycin therapy for Clostridium difficile-induced diarrhea. A randomized double-blind trial.
Arch Intern Med. 1986 Jun;146(6):1101-4.
8
Treatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens.
Am J Med. 1989 Jan;86(1):15-9. doi: 10.1016/0002-9343(89)90223-4.
9
Bacteriotherapy for chronic relapsing Clostridium difficile diarrhoea in six patients.
Lancet. 1989 May 27;1(8648):1156-60. doi: 10.1016/s0140-6736(89)92749-9.
10
Cytotoxicity assay in antibiotic-associated colitis.
J Infect Dis. 1979 Nov;140(5):765-70. doi: 10.1093/infdis/140.5.765.
Zotero 插件